RNS8 Aug 2017 16:48
Tissue Regenix Group plc
("Tissue Regenix" or the "Company")
Result of General Meeting and Total Voting Rights
Leeds, 8 August 2017 - Tissue Regenix (AIM:TRX) is pleased to announce that at the General Meeting held earlier today, all the proposed resolutions set out in the circular dated 21 July 2017, including those necessary to implement the Offer and the Acquisition announced by the Company on 20 July 2017, were duly passed.
Accordingly, the Company has applied to the London Stock Exchange for 400,000,000 New Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur at 8.00 a.m. on 9 August 2017.
Following admission of the 400,000,000 New Ordinary Shares to trading on AIM, the total number of Ordinary Shares with voting rights in issue will be 1,161,068,755.
Upon admission, the New Ordinary Shares will be issued, credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company.
Unless expressly defined in this announcement, all capitalised terms used in this announcement have the meanings stated in the announcement made on 20 July 2017.
For more Information:
Tissue Regenix Group plc Tel: 07920 272 441
Caitlin Pearson, Corporate Communications Director